Literature DB >> 30852587

Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV.

Julia A Aepfelbacher1, Julia Balmaceda1, Julia Purdy2, Aviva Mattingly1, Kirsten Zambell3, Karyn Hawkins4, Cheryl Chairez1, Kara Anne Curl1, Nicola Dee1, Colleen Hadigan1.   

Abstract

Little is known about the effects of lifelong human immunodeficiency virus (HIV) or antiretroviral therapy on hepatic steatosis and fibrosis. Using transient elastography, we evaluated 46 young adults with lifelong HIV and 20 matched HIV-negative controls. Steatosis was present in 33% of persons with HIV and only 10% of controls (P = .04). Hepatic fibrosis scores were not elevated and did not differ between groups. Metabolic parameters, particularly increased waist circumference, and not HIV-specific factors, were significantly associated with steatosis. While this finding should be examined in larger cohorts, modifiable metabolic disturbances may be important targets to optimize liver health in this population. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  AIDS; HIV; hepatic steatosis; nonalcoholic fatty liver disease; young adults

Mesh:

Year:  2019        PMID: 30852587      PMCID: PMC6581896          DOI: 10.1093/infdis/jiz096

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Authors:  Maud Lemoine; Lambert Assoumou; Stephane De Wit; Pierre-Marie Girard; Marc Antoine Valantin; Christine Katlama; Coca Necsoi; Pauline Campa; Anja D Huefner; Julian Schulze Zur Wiesch; Hayette Rougier; Jean-Philippe Bastard; Hartmut Stocker; Stefan Mauss; Lawrence Serfaty; Vlad Ratziu; Yves Menu; Jerome Schlue; Georg Behrens; Pierre Bedossa; Jacqueline Capeau; Patrick Ingiliz; Dominique Costagliola
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-01       Impact factor: 3.731

Review 2.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.

Authors:  Anna M Diehl; Christopher Day
Journal:  N Engl J Med       Date:  2017-11-23       Impact factor: 91.245

3.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

4.  Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

Authors:  Thomas Karlas; David Petroff; Magali Sasso; Jian-Gao Fan; Yu-Qiang Mi; Victor de Lédinghen; Manoj Kumar; Monica Lupsor-Platon; Kwang-Hyub Han; Ana C Cardoso; Giovanna Ferraioli; Wah-Kheong Chan; Vincent Wai-Sun Wong; Robert P Myers; Kazuaki Chayama; Mireen Friedrich-Rust; Michel Beaugrand; Feng Shen; Jean-Baptiste Hiriart; Shiv K Sarin; Radu Badea; Kyu Sik Jung; Patrick Marcellin; Carlo Filice; Sanjiv Mahadeva; Grace Lai-Hung Wong; Pam Crotty; Keiichi Masaki; Joerg Bojunga; Pierre Bedossa; Volker Keim; Johannes Wiegand
Journal:  J Hepatol       Date:  2016-12-28       Impact factor: 25.083

Review 5.  Liver disease in the HIV-infected individual.

Authors:  Jennifer C Price; Chloe L Thio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

6.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

Authors:  Stuart McPherson; Tim Hardy; Elsbeth Henderson; Alastair D Burt; Christopher P Day; Quentin M Anstee
Journal:  J Hepatol       Date:  2014-12-01       Impact factor: 25.083

Review 7.  Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.

Authors:  James B Maurice; Amee Patel; Alasdair J Scott; Krish Patel; Mark Thursz; Maud Lemoine
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

8.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.

Authors:  J Macías; L M Real; A Rivero-Juárez; N Merchante; A Camacho; K Neukam; A Rivero; M Mancebo; J A Pineda
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

10.  Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.

Authors:  Raphael Mohr; Christoph Boesecke; Leona Dold; Robert Schierwagen; Carolynne Schwarze-Zander; Jan-Christian Wasmuth; Insa Weisensee; Jürgen Kurt Rockstroh; Jonel Trebicka
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

View more
  4 in total

1.  Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection.

Authors:  Mandana Khalili; Wendy C King; David E Kleiner; Mamta K Jain; Raymond T Chung; Mark Sulkowski; Mauricio Lisker-Melman; David K Wong; Marc Ghany; Arun Sanyal; Richard K Sterling
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

2.  Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Authors:  Veeral H Ajmera; Edward R Cachay; Christian B Ramers; Shirin Bassirian; Seema Singh; Richele Bettencourt; Lisa Richards; Gavin Hamilton; Michael Middleton; Katie Fowler; Claude Sirlin; Rohit Loomba
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

3.  Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children.

Authors:  Penelope C Rose; Etienne D Nel; Mark F Cotton; Richard D Pitcher; Kennedy Otwombe; Sara H Browne; Steve Innes
Journal:  Front Pediatr       Date:  2022-06-09       Impact factor: 3.569

4.  HIV and the liver.

Authors:  Kenneth E Sherman; Marion G Peters; David L Thomas
Journal:  Top Antivir Med       Date:  2019-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.